LR-CHOP-21 regimen: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} ==Overview== {{PAGENAME}} refers to a chemotherapeutic regimen consisting of lenalidomide, rituximab, cyclophosphamide,..." |
No edit summary |
||
| Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a chemotherapeutic regimen consisting of [[lenalidomide]], [[rituximab]], [[cyclophosphamide]], [[doxorubicin]], [[vincristine]], and [[prednisolone]]given every 21 days has high activity in relapsed or refractory [[diffuse large B-cell lymphoma]] (DLBCL).<ref name="pmid24831981">{{cite journal| author=Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G et al.| title=Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. | journal=Lancet Oncol | year= 2014 | volume= 15 | issue= 7 | pages= 730-7 | pmid=24831981 | doi=10.1016/S1470-2045(14)70191-3 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24831981 }} </ref> | {{PAGENAME}} refers to a chemotherapeutic regimen consisting of [[lenalidomide]], [[rituximab]], [[cyclophosphamide]], [[doxorubicin]], [[vincristine]], and [[prednisolone]]given every 21 days has high activity in relapsed or refractory [[diffuse large B-cell lymphoma]] (DLBCL).<ref name="pmid24831981">{{cite journal| author=Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G et al.| title=Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. | journal=Lancet Oncol | year= 2014 | volume= 15 | issue= 7 | pages= 730-7 | pmid=24831981 | doi=10.1016/S1470-2045(14)70191-3 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24831981 }} </ref> | ||
| Line 9: | Line 8: | ||
==Regimen== | ==Regimen== | ||
{{chemo|L|Lenalidomide}} | {{chemo|L|Lenalidomide}} | ||
{{chemo|R|Rituximab}} | {{chemo|R|Rituximab}} | ||
{{chemo|C|Cyclophosphamide}} | {{chemo|C|Cyclophosphamide}} | ||
{{chemo|H|Doxorubicin (Hydroxydoxorubicin Hydrochloride)}} | {{chemo|H|Doxorubicin (Hydroxydoxorubicin Hydrochloride)}} | ||
| Line 18: | Line 20: | ||
==Indications== | ==Indications== | ||
*Relapsed or refractory [[diffuse large B-cell lymphoma]] (DLBCL).<ref name="pmid24831981">{{cite journal| author=Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G et al.| title=Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. | journal=Lancet Oncol | year= 2014 | volume= 15 | issue= 7 | pages= 730-7 | pmid=24831981 | doi=10.1016/S1470-2045(14)70191-3 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24831981 }} </ref> | *Relapsed or refractory [[diffuse large B-cell lymphoma]] (DLBCL).<ref name="pmid24831981">{{cite journal| author=Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G et al.| title=Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. | journal=Lancet Oncol | year= 2014 | volume= 15 | issue= 7 | pages= 730-7 | pmid=24831981 | doi=10.1016/S1470-2045(14)70191-3 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24831981 }} </ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Chemotherapy regimens]] | [[Category:Chemotherapy regimens]] | ||
Revision as of 15:01, 27 March 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
LR-CHOP-21 regimen refers to a chemotherapeutic regimen consisting of lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolonegiven every 21 days has high activity in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[1]
Regimen
LLenalidomide
RRituximab
CCyclophosphamide
HDoxorubicin (Hydroxydoxorubicin Hydrochloride)
OVincristine (Oncovin)
PPrednisolone
Indications
- Relapsed or refractory diffuse large B-cell lymphoma (DLBCL).[1]
References
- ↑ 1.0 1.1 Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G; et al. (2014). "Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial". Lancet Oncol. 15 (7): 730–7. doi:10.1016/S1470-2045(14)70191-3. PMID 24831981.